Welcome to MorphoSys

Founded some 20 years ago, MorphoSys is today one of the world's leading biotechnology companies. From a pure antibody platform enterprise, MorphoSys has matured into a renowned biopharmaceutical company with a rich pipeline of future therapeutic antibody products and a sustainable dual therapeutic business model. The Company’s aim is to continue pushing the boundaries of antibody generation in the industry – to engineer the medicines of tomorrow.

 

Innovation Capital

A new initiative through which MorphoSys provides innovation capital to promising start-ups.

 

Q3 2014 Report

Have a look at MorphoSys's Nine Months' Report 2014

 

News

  • 19/12/2014 // MorphoSys's Partner Roche Provides Update on Trial of Gantenerumab in Prodromal Alzheimer's Patients

    more …

  • 15/12/2014 // MorphoSys's MOR208 Program Receives Positive Opinion for Orphan Medicinal Product Designation from EMA for DLBCL

    more …

Find more releases in the news overview

Partnering

MorphoSys is interested in antibodies and biologics at late preclinical or early clinical stages.

 

MOR208@ASH2014

ASH posters on MOR208 monotherapy in NHL and CLL/SLL.